Uncomplicated Pelvic Inflammatory Disease. Treatment With Moxifloxacin.
NCT ID: NCT00683865
Last Updated: 2014-10-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
749 participants
INTERVENTIONAL
2003-04-30
2004-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Moxifloxacin Versus Ofloxacin Plus Metronidazole in Uncomplicated Pelvic Inflammatory Disease: Multicenter Randomized Controlled Trials
NCT01799356
A Trial Comparing Moxifloxacin Versus Levofloxacin Plus Metronidazole In Uncomplicated Pelvic Inflammatory Disease
NCT00453349
Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection
NCT01069900
A Study to Assess the Efficacy and Safety of IV/PO Moxifloxacin in Subjects With Community-acquired Pneumonia
NCT00717561
Moxifloxacin Versus Amoxicillin Clavulanic Acid in Treatment of Acute Exacerbation of Chronic Bronchitis
NCT00656747
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1
Ofloxacin
Ofloxacin 400 mg po bid plus metronidazole 500 mg po bid for 14 days
Arm 2
Avelox (Moxifloxacin, BAY12-8039)
Moxifloxacin 400 mg po od for 14 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ofloxacin
Ofloxacin 400 mg po bid plus metronidazole 500 mg po bid for 14 days
Avelox (Moxifloxacin, BAY12-8039)
Moxifloxacin 400 mg po od for 14 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adnexal tenderness on bimanual vaginal examination,
* Temperature \> 38.0°C; - Elevated C-reactive protein value (CRP);
* Signed PIC/IC
Exclusion Criteria
* Abnormal lab values
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bayer Study Director
Role: STUDY_DIRECTOR
Bayer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bordeaux, , France
Brive-la-Gaillarde, , France
Cenon, , France
Colombes, , France
Créteil, , France
Domont, , France
Lille, , France
Montauban, , France
Montpellier, , France
Muret, , France
Nancy, , France
Paris, , France
Paris, , France
Toulouse, , France
München, Bavaria, Germany
Rostock, Mecklenburg-Vorpommern, Germany
Essen, North Rhine-Westphalia, Germany
Grevenbroich, North Rhine-Westphalia, Germany
Leverkusen, North Rhine-Westphalia, Germany
Wuppertal, North Rhine-Westphalia, Germany
Berlin, State of Berlin, Germany
Berlin, State of Berlin, Germany
Athens, Attica, Greece
Athens, Attica, Greece
Dourouti-Ioannina, Ioannina, Greece
Budapest, , Hungary
Budapest, , Hungary
Eger, , Hungary
Győr, , Hungary
Kecskemét, , Hungary
Pavia, , Italy
Perugia, , Italy
Trieste, , Italy
Klaipėda, , Lithuania
Vilnius, , Lithuania
Vilnius, , Lithuania
Vilnius, , Lithuania
Bialystok, , Poland
Krakow, , Poland
Lodz, , Poland
Lublin, , Poland
Owock, , Poland
Poznan, , Poland
Warsaw, , Poland
Warsaw, , Poland
Moscow, , Russia
Moscow, , Russia
Moscow, , Russia
Bloemfontein, Free State, South Africa
Johannesburg, Gauteng, South Africa
Johannesburg, Gauteng, South Africa
Pretoria, Gauteng, South Africa
Pretoria, Gauteng, South Africa
Durban, KwaZulu-Natal, South Africa
Cape Town, Western Cape, South Africa
Cape Town, Western Cape, South Africa
Gothenburg, , Sweden
Linköping, , Sweden
Lund, , Sweden
Trollhättan, , Sweden
Varberg, , Sweden
Bristol, Avon, United Kingdom
London, Greater London, United Kingdom
London, Greater London, United Kingdom
London, Greater London, United Kingdom
Southampton, Hampshire, United Kingdom
Nottingham, Nottinghamshire, United Kingdom
Birmingham, West Midlands, United Kingdom
Hvidovre, , Denmark
Odense C, , Denmark
Roskilde, , Denmark
Hämeenlinna, , Finland
Helsinki, , Finland
Joensuu, , Finland
Kotka, , Finland
Antony, , France
Beaumont, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10995
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.